Citations

Clear

2511 citation(s) found for "Yang, Yu".

In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma
Yang, Man , Hlady, Ryan A. , Ho, Thai H. , Robertson, Keith D. , Zhou, Dan , Ho, Thai , Robertson, Keith D

Mayo Clinic

Cancer Medicine | July 30, 2019 | Volume: 8 | Issue: 12 | Pages: 5760-5768

10.1002/cam4.2402 | PMID 31361072 Get It

AbstractThere are currently no effective treatments for advanced‐stage papillary renal cell carcinoma (PRCC). The goal of this study is to define potential DNA methylation‐based markers and treatment targets for advanced‐stage type 2 PRCC. Progressive DNA methylation changes and copy number variation (CNV) from localized to advanced‐stage type 2 PRCC are analyzed by using methylation data generated by TCGA's kidney renal papillary cell carcinoma (TCGA‐KIRP, 450k array) project. Survival analyses are performed for the identified biomarkers and genes with CNV. In addition, expression of the corresponding genes is investigated by RNA‐seq analysis. Progressive methylation changes in several CpGs from localized to advanced‐stage type 2 PRCC are observed. Four CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) in particular are identified as markers for differentiating between localized and advanced‐stage type 2 PRCC. Copy number analysis reveals that copy gain of PTK7 mostly occurs in advanced‐stage type 2 PRCC. Both the four CpG methylation changes and PTK7 copy number gain are associated with patient survival. RNA‐seq analysis demonstrates that PTK7 copy gain leads to higher PTK7 expression relative to tumors without copy number gain. Moreover, PTK7 is significantly upregulated from localized to advanced‐stage type 2 PRCC and is linked to cancer cell invasion. In conclusion, DNA methylation markers that differentiate between localized and advanced‐stage type 2 PRCC may serve as useful markers for disease staging or outcome, while PTK7 copy gain represents a potential treatment target for advanced‐stage type 2 PRCC. Stepwise methylation changes and copy number gain also associate with disease stage in PRCC patients.
Molecular profiling of long-term IDH-wildtype glioblastoma survivors
Yang, Jie , Decker, Paul A. , Kollmeyer, Thomas M. , Kosel, Matthew , Mladek, Ann C. , Caron, Alissa, Kitange, Gaspar J. , Sicotte, Hugues , Youland, Ryan S. , Voss, Jesse S. , Kolsky, K. L., Meyer, Fredric B. , Parney, Ian, Kipp, Benjamin R. , Sulman, Erik P. , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Burgenske, Danielle M. , Caron, Alissa A, Gupta, Shiv K. , Fritcher, Emily G. Barr , Kolsky, Kathryn L, Parney, Ian J, Kollmeyer, Thomas , Sulman, Erik P , Mladek, Ann C , Decker, Paul A. , Vaubel, Rachael A. , Remonde, Dioval , Ida, Cristiane M. , Lachance, Daniel Honore , Giannini, Caterina , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1458-1469

10.1093/neuonc/noz129 | PMID 31346613 Get It

AbstractBackgroundGlioblastoma (GBM) represents an aggressive cancer type with a median survival of only 14 months. With fewer than 5% of patients surviving 5 years, comprehensive profiling of these rare patients could elucidate prognostic biomarkers that may confer better patient outcomes. We utilized multiple molecular approaches to characterize the largest patient cohort of isocitrate dehydrogenase (IDH)–wildtype GBM long-term survivors (LTS) to date.MethodsRetrospective analysis was performed on 49 archived formalin-fixed paraffin embedded tumor specimens from patients diagnosed with GBM at the Mayo Clinic between December 1995 and September 2013. These patient samples were subdivided into 2 groups based on survival (12 LTS, 37 short-term survivors [STS]) and subsequently examined by mutation sequencing, copy number analysis, methylation profiling, and gene expression.ResultsOf the 49 patients analyzed in this study, LTS were younger at diagnosis (P = 0.016), more likely to be female (P = 0.048), and MGMT promoter methylated (UniD, P = 0.01). IDH-wildtype STS and LTS demonstrated classic GBM mutations and copy number changes. Pathway analysis of differentially expressed genes showed LTS enrichment for sphingomyelin metabolism, which has been linked to decreased GBM growth, invasion, and angiogenesis. STS were enriched for DNA repair and cell cycle control networks.ConclusionsWhile our findings largely report remarkable similarity between these LTS and more typical STS, unique attributes were observed in regard to altered gene expression and pathway enrichment. These attributes may be valuable prognostic markers and are worth further examination. Importantly, this study also underscores the limitations of existing biomarkers and classification methods in predicting patient prognosis.
Use of Acupuncture in Overweight/Obese Women with Polycystic Ovary Syndrome
Yang, Juan , Chon, Tony Y. , Bauer, Brent A.

Mayo Clinic

Medical Acupuncture | July 22, 2019 | Volume: 31 | Issue: 5 | Pages: 267-268

10.1089/acu.2019.1375 | PMID 31624524 Get It

Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Yang, Ju Dong , Ahmed, Fowsiyo , Mara, Kristin C. , Addissie, Benyam D., Allen, Alina M. , Roberts, Lewis R. , Roberts, Lewis R , Mara, Kristin C , Allen, Alina M , Yang, Ju Dong , Gores, Gregory J.

Mayo Clinic

Hepatology | July 16, 2019 | Volume: 71 | Issue: 3 | Pages: 907-916

10.1002/hep.30858 | PMID 31309602 Get It

Diabetes increases the risk of liver disease progression and cirrhosis development in patients with nonalcoholic steatohepatitis (NASH). The association between diabetes and the risk of hepatocellular carcinoma (HCC) in NASH patients with cirrhosis is not well quantified. All patients with the diagnosis of NASH cirrhosis seen at Mayo Clinic Rochester between January 2006 and December 2015 were identified. All adult liver transplant registrants with NASH between 2004 and 2017 were identified using the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation registry for external validation. Cox proportional hazard analysis was performed to investigate the association between diabetes and HCC risk. Among 354 Mayo Clinic patients with NASH cirrhosis, 253 (71%) had diabetes and 145 (41%) were male. Mean age at cirrhosis evaluation was 62. During a median follow‐up of 47 months, 30 patients developed HCC. Diabetes was associated with an increased risk of developing HCC in univariate (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.1‐11.9; P = 0.04) and multivariable analysis (HR = 4.2; 95% CI = 1.2‐14.2; P = 0.02). In addition, age (per decade, HR = 1.8; 95% CI = 1.2‐2.6; P < 0.01) and low serum albumin (HR = 2.1; 95% CI = 1.5‐2.9; P < 0.01) were significantly associated with an increased risk of developing HCC in multivariable analysis. Other metabolic risk factors, including body mass index, hyperlipidemia, and hypertension, were not associated with HCC risk. Among UNOS NASH registrants (N = 6,630), 58% had diabetes. Diabetes was associated with an increased risk of developing HCC in univariate (HR = 1.4; 95% CI = 1.1‐1.8; P < 0.01) and multivariable (HR = 1.3; 95% CI = 1.0‐1.7; P = 0.03) analysis. Conclusion: Diabetes is associated with an increased risk of HCC in patients with NASH cirrhosis.
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Goadsby, Peter J. , Leone, Massimo , Bardos, Jennifer, Oakes, Tina M. , Millen, Brian A. , Zhou, Chunmei, Dowsett, Sherie A. , Aurora, Sheena K. , Ahn, Andrew H. , Yang, Jyun-Yan, Conley, Robert R., Martinez, James M. , Bardos, Jennifer N, Goadsby, Peter J , Dodick, David W.

Mayo Clinic

New England Journal of Medicine | July 10, 2019 | Volume: 381 | Issue: 2 | Pages: 132-141

10.1056/nejmoa1813440 | PMID 31291515 Get It

Double-orifice mitral valve associated and bicuspid aortic valve: forme fruste of Shone's complex?
Foley, Thomas A. , Eidem, Benjamin W., Yang, Li-Tan, Yang, Li‐Tan , Crestanello, Juan A. , Michelena, Héctor I.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | July 9, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjci/jez195 | PMID 31302682 Get It

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, Michele , Adusumilli, Prasad S. , Alexander, H. Richard , Baas, Paul, Bardelli, Fabrizio , Bononi, Angela , Bueno, Raphael , Felley‐Bosco, Emanuela , Galateau-Sallé, Françoise , Jablons, David M., Mansfield, Aaron S. , Minaai, Michael , Severson, David T. , Woodard, Gavitt A. , Yang, Haining , Pass, Harvey I. , Mansfield, Aaron S , Baas, Paul, de Perrot, Marc , Pesavento, Patricia A. , Rusch, Valerie W. , Taioli, Emanuela , Tsao, Anne S. , Zauderer, Marjorie G.

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 8, 2019 | Volume: 69 | Issue: 5 | Pages: 402-429

10.3322/caac.21572 | PMID 31283845 Get It

Abstract Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1‐asssociated protein 1 ( BAP1 ) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.
Rapid Antimicrobial Susceptibility Testing of Patient Urine Samples Using Large Volume Free-Solution Light Scattering Microscopy
Mo, Manni , Yang, Yunze , Zhang, Fenni , Jing, Wenwen , Iriya, Rafael , Popovich, John, Grys, Thomas E. , Haydel, Shelley E. , Tao, Nongjian , Wang, Shaopeng , Grys, Thomas, Zhang, Fenni , Haydel, Shelley E , Grys, Thomas E , Popovich, John, Wang, Shaopeng , Jing, Wenwen

Mayo Clinic

Analytical Chemistry | June 28, 2019 | Volume: 91 | Issue: 15 | Pages: 10164-10171

10.1021/acs.analchem.9b02174 | PMID 31251566 Get It

Metabolic Syndrome Induces Release of Smaller Extracellular Vesicles from Porcine Mesenchymal Stem Cells
Conley, Sabena M., Shook, John E., Zhu, Xiang-Yang, Eirin, Alfonso , Jordan, Kyra L., Woollard, John R. , Isik, Busra , Hickson, LaTonya J. , Puranik, Amrutesh S. , Lerman, Lilach O. , Hickson, LaTonya J , Eirin, Alfonso , Puranik, Amrutesh S , Shook, John E.

Mayo Clinic

Cell Transplantation | June 28, 2019 | Volume: 28 | Issue: 9-10 | Pages: 1271-1278

10.1177/0963689719860840 | PMID 31250656 Get It

Mesenchymal stromal/stem cells (MSCs) belong to the endogenous cellular reparative system, and can be used exogenously in cell-based therapy. MSCs release extracellular vesicles (EVs), including exosomes and microvesicles, which mediate some of their therapeutic activity through intercellular communication. We have previously demonstrated that metabolic syndrome (MetS) modifies the cargo packed within swine EV, but whether it influences their phenotypical characteristics remains unclear. This study tested the hypothesis that MetS shifts the size distribution of MSC-derived EVs. Adipose tissue-derived MSC-EV subpopulations from Lean ( n = 6) and MetS ( n = 6) pigs were characterized for number and size using nanoparticle-tracking analysis, flow cytometry, and transmission electron microscopy. Expression of exosomal genes was determined using next-generation RNA-sequencing (RNA-seq). The number of EV released from Lean and MetS pig MSCs was similar, yet MetS-MSCs yielded a higher proportion of small-size EVs (202.4 ± 17.7 nm vs. 280.3 ± 15.1 nm), consistent with exosomes. RNA-seq showed that their EVs were enriched with exosomal markers. Lysosomal activity remained unaltered in MetS-MSCs. Therefore, MetS alters the size distribution of MSC-derived EVs in favor of exosome release. These observations may reflect MSC injury and membrane recycling in MetS or increased expulsion of waste products, and may have important implications for development of adequate cell-based treatments.